Immunomodulatory effects of macrolides during community-acquired pneumonia: A literature review

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 530-540

  Kovaleva, Alexandra ^a   Remmelts, Hilde H F ^a,b   Rijkers, Ger T ^c   Hoepelman, Andy I M ^a   Biesma, Douwe H ^a,c   Oosterheert, Jan Jelrik ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GELDERSE VALLEI HOSPITAL   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Antibacterials; Cytokines; Inflammation

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CETHROMYCIN; CLARITHROMYCIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ERYTHROMYCIN; GAMMA INTERFERON; HMR 3004; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; RANTES; ROXITHROMYCIN; TELITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANTIMICROBIAL ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL COUNT; CELL DEATH; CELL FUNCTION; CELL INFILTRATION; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; EMBASE; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; LUNG ALVEOLUS EPITHELIUM; LUNG ENDOTHELIUM; LUNG LAVAGE; MEDLINE; NEUTROPHIL; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYSTEM; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; MACROLIDES; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 84856960076     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr520     Document Type: Article

References (42)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61-6.
2. Anas AA, Wiersinga WJ, de Vos AF et al. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010; 68: 147-52.
3. Meijvis SC, Grutters JC, Thijsen SF et al. Therapy in pneumonia: what is beyond antibiotics? Neth J Med 2011; 69: 21-6.
4. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-615.
5. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community acquired respiratory tract infections and chronic conditions? J Antimicrob Chemother 2005; 55: 10-21.
6. Dudas V, Hopefl A, Jacobs R et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34: 446-52.
7. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-42.
8. Houck PM, MacLehose RF, Niederman MS et al. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119: 1420-6.
9. Martinez JA, Horcajada JP, Almela M et al. Addition of a macrolide to a b-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-95.
10. Gleason PP, Meehan TP, Fine JM et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72.
11. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107: 34S-43S.
12. Moldoveanu B, Otmishi P, Jani P et al. Inflammatory mechanisms in the lung. J Inflamm Res 2009; 2: 1-11.
13. Backus GS, Howden R, Fostel J et al. Protective role of interleukin-10 in ozone-induced pulmonary inflammation. Environ Health Perspect 2010; 118: 1721-7.
14. Uriarte SM, Molestina RE, Miller RD et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-a. J Infect Dis 2002; 185: 1631-6.
15. Qian J, Bai C, Wang G. Study on human tracheal bronchial epithelial cells secreting cytokines in vitro by nontypeable Haemophilus influenzae. Chest 2010; 138: 599A.
16. Schultz MJ, Speelman P, Zaat S et al. Erythromycin inhibits tumor necrosis factor a and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob Agents Chemother 1998; 42: 1605-9.
17. Schultz MJ, Speelman P, Hack CE et al. Intravenous infusion of erythromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae. J Antimicrob Chemother 2000; 46: 235-40.
18. Guchelaar HJ, Schultz MJ, van der Poll T et al. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-a and interleukin-6 production. Fundam Clin Pharmacol 2001; 15: 419-24.
19. Khair OA, Devalia JL, Abdelaziz MM et al. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995; 8: 1451-7.
20. Kurata S, Taguchi H, Sasaki T et al. Antimicrobial and immunomodulatory effect of clarithromycin on macrolide-resistant Mycoplasma pneumoniae. J Med Microbiol 2010; 59: 693-701.
21. van Langevelde P, van Dissel JT, Ravensbergen E et al. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob Agents Chemother 1998; 42: 3073-8.
22. van Langevelde P, Ravensbergen E, Grashoff P et al. Antibiotic-induced cell wall fragments of Staphylococcus aureus increase endothelial chemokine secretion and adhesiveness for granulocytes. Antimicrob Agents Chemother 1999; 43: 2984-9.
23. Leiva M, Ruiz-Bravo A, Jimenez-Valera M. Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. Chest 2008; 134: 20-9.
24. Kushiya K, Nakagawa S, Taneike I et al. Inhibitory effect of antimicrobial agents and anisodamine on the staphylococcal superantigenic toxin-induced overproduction of proinflammatory cytokines by human peripheral blood mononuclear cells. J Infect Chemother 2005; 11: 192-5.
25. Lagrou K, Peetermans WE, Jorissen M et al. Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J Antimicrob Chemother 2000; 46: 717-23.
26. Kazachkov MY, Hu PC, Carson JL et al. Release of cytokines by human nasal epithelial cells and peripheral blood mononuclear cells infected with Mycoplasma pneumoniae. Exp Biol Med (Maywood) 2002; 227: 330-5.
27. Koch CC, Esteban DJ, Chin AC et al. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J Antimicrob Chemother 2000; 46: 19-26.
28. Chmura K, Bai X, Nakamura M et al. Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells. Am J Physiol Lung Cell Mol Physiol 2008; 295: L220-30.
29. Rios AM, Fonseca-Aten M, Mejias A et al. Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrobial Agents Chemother 2005; 49: 3970-3.
30. Rios AM, Mejias A, Chavez-Bueno S et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob Agents Chemother 2004; 48: 2897-904.
31. Hardy RD, Rios AM, Chavez-Bueno S et al. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrobial Agents Chemother 2003; 47: 1614-20.
32. Duong M, Simard M, Bergeron Y et al. Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob Agents Chemother 2001; 45: 252-62.
33. Tagliabue C, Salvatore CM, Techasaensiri C et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008; 198: 1180-8.
34. Nakamura S, Yanagihara K, Araki N et al. Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. Antimicrob Agents Chemother 2010; 54: 757-62.
35. Yasuda Y, Kasahara K, Mizuno F et al. Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. Antimicrob Agents Chemother 2007; 51: 1741-52.
36. Hirao S, Wada H, Nakagaki K et al. Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone. FEMS Immunol Med Microbiol 2011; 62: 182-9.
37. Duong M, Simard M, Bergeron Y et al. Immunomodulating effects of HMR 3004 on pulmonary inflammation caused by heat-killed Streptococcus pneumoniae in mice. Antimicrobial Agents Chemother 1998; 42: 3309-12.
38. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003; 47: 2450-7.
39. Demartini G, Esposti D, Marthyn P et al. Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNg and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother 2004; 16: 82-5.
40. Lange M, Hamahata A, Traber DL et al. A murine model of sepsis following smoke inhalation injury. Biochem Biophys Res Commun 2010; 391: 1555-60.
41. Vazifeh D, Abdelghaffar H, Labro MT. Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin. Antimicrob Agents Chemother 2002; 46: 1364-74.
42. Herrera-Insua I, Perez P, Ramos C et al. Synergistic effect of azithromycin on the phagocytic killing of Staphylococcus aureus by human polymorphonuclear leukocytes. Eur J Clin Microbiol Infect Dis 1997; 16: 13-6.